Compare Ginkgo Bioworks Holdings Inc (DNA) vs SMX Security Matters plc (SMX) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

SMX trades at $4.21, up 7.95% today, but exhibits severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22% for 2025. The technical outlook is bearish based on moving averages, though oscillators like the RSI signal oversold conditions. Recent news highlights the company's focus on its Digital Material Passport platform for recycled plastics and material traceability, aiming to capitalize on circular economy trends.

The investment outlook is highly speculative. While the stock appears cheap on P/B (0.09) and EV/EBITDA (0.02) multiples, this reflects extreme financial losses and operational cash burn. Positive media coverage contrasts with the fundamental reality, creating significant risk. Upside depends entirely on the successful commercialization of its technology, which remains unproven given the current lack of revenue.